StemCell Therapy

As wearables companies continue to add new health and wellness capabilities, Apple showed off its latest smartwatch Tuesday with an ability to measure users' blood oxygen.

The new Apple Watch Series 6 expands the health capabilities of previous Apple Watch models with a new feature that measures the oxygen saturation of the users bloodso they can better understand their overall fitness and wellness, the company said as they unveiled the watch during Apple'sfall product event.

Oxygen saturation, or SpO2, represents the percentage of oxygen being carried by red blood cells from the lungs to the rest of the body, and indicates how well this oxygenated blood is being delivered throughout the body.

Apple Watch Series 6 completely redefines what a watch can do, said Jeff Williams, Apples chief operating officer in a statement. With powerful new features, including a Blood Oxygen sensor and app,Apple Watch becomes even more indispensable by providing further insight into overall well-being."

The blood oxygen app measurements are only designed for general fitness and wellness purposes are not intended for medical use, including self-diagnosis or consultation with a doctor, the tech giant said.

RELATED:Fitbit's ECG app gets FDA nod to track heart rhythm irregularities

Companies outside of healthcare, like Apple, see that migrating care away from intensive settings is the future, according toMichael Abrams, co-founder and managing partner at global healthcare consulting firm Numerof & Associates.

"They, and other tech companies, are currently working to seize the business opportunity that that reality presents, and if hospitals and health systems want to find future success, its time they follow suit," he said.

Considering how many Americans have had to shelter in place and pay close attention to their own health and wellness this year, its no surprise that Apple, Google and most recently Amazon have added more health features to their wearable devices, said

"Apples new blood oxygen monitoring is particularly timely, and more broadly, another example of tech both hearing and answering consumers call for a better way to manage care from the comfort of home," Abrams said.

Apple also has unveiled a new fitness app designed for its smartwatches, and CVS Health has signed on to offer it to select commercial Aetnaand Caremark members.

The companyplans to partner withthe government of Singapore on a national health initiaitve using Apple Watch.

The initiative, called LumiHealth, is a personalized program to encourage healthy activity and behaviors using fitness tracking and apps. Created in collaboration with a team of physicians and public health experts, LumiHealth features challenges designed to help users sleep better, move more, eat well, and live more mindfully.LumiHealth also reminds users to go for health screenings andimmunizations.

Singapore has one of the worlds leading healthcare systems, and we are thrilled to be partnering with them to incorporate Apple Watch and LumiHealth into their holistic approach to well-being, Williams said.

Apple will sponsor three studies to validate the feature and its benefits andexplore how blood oxygen levels can be used in future health applications.The company will work with researchers at Anthem and the University of California, Irvine toexamine how longitudinal measurements of blood oxygen and other physiological signals can help manage and control asthma.

RELATED:Competing with Apple and Fitbit, Amazon launches health wearable that tracks activity, body fat, emotions

Apple also plans to work with the Ted Rogers Centre for Heart Research and the Peter Munk Cardiac Centre at the University Health Networkto better understand how blood oxygen measurements and other Apple Watch metrics can help with management of heart failure.

Meanwhile, the Seattle Flu Study at the Brotman Baty Institute for Precision Medicine and faculty from the University of Washington School of Medicine will examine how signals from apps on Apple Watch, such as heart rate and blood oxygen, could serve as early signs of respiratory conditions like influenza and COVID-19.

The battle to lead the consumer fitness tracker market is heating up as Amazon recently launched a fitness tracker, called Halo, that track activity, body fat, and emotions. Companies like Amazon, Apple and Fitbit are all focusing onpivoting theirwearables from just fun accessories to health devices.

Fitbit just announced that has gained medical device clearances in the U.S. and Europe for its smartwatch electrocardiogram appto track users'heart rhythms for signs of atrial fibrillation.

The company's latest device, FitbitSense, tracks heart rate variability, breathing rate and blood-oxygen saturation, or SpO2. Fitbit Sensealso will have anon-wrist skin temperature sensor that can help detect potential signs of illness.

Excerpt from:
Apple steps up its focus on health with new blood oxygen sensor and population health initiative in Singapore - FierceHealthcare

This Automation Testing market document highlights key market dynamics of sector along with the current market scenario and future prospects of the sector. This report figures out market landscape, brand awareness, latest trends, possible future issues, industry trends and customer behavior so that business can stand high in the crowd. This market report is the most appropriate solution for the business requirements in many ways which also assists with the informed decision making and smart working. The Automation Testing report also encompasses market overview, premium insights, key insights and company profiles in detail of the key market players.

Automation Testing Market accounted for USD 2.36 billion in 2017 and is projected to grow at a CAGR of 3.0% the forecast period of 2020 to 2025.

Automation Testing marketResearch Report is a valuable source of insightful data for business strategies. It provides the Global Automation Testing industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the Automation Testing Market dominated players, distributor and vendors analysis, value structure chain analysis. The Global Automation Testing market study provides comprehensive data about market segmentation, drivers, restrains and regional market analysis by country level which enhances the understanding, scope and application of this Automation Testing Market report. Delivering the key insights pertaining to this industry, the report provides an in-depth analysis of the latest trends, present and future business scenario, market size and share of Major Players suchSTAr Technologies Inc., Tesec Corporation, Roos Instruments, Inc., Marvin Test Solutions Inc. and Danaher Corporation, Teradyne Inc., Advantest Corporation, Capgemini, Wipro, Accenture, TCS, Infosys Ltd. among others.

For Better Understanding, Download Free Sample PDF Brochure of Automation Testing Market Research Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-automation-testing-market

Market Dynamics:

Set of qualitative information that includes PESTEL Analysis, PORTER Five Forces Model, Value Chain Analysis and Macro Economic factors, Regulatory Framework along with Industry Background and Overview.

Global Automation Testing Research Methodology

Data Bridge Market Research presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers.

Major Drivers and Restraints of the Automation Testing Industry

Growing demand for personalized medicine is expected to create new opportunity for the Automation Testing market.

Clinical trial digitization allows the processing in different forms of voluminous patient-related data. Such data are being used by pharmaceutical companies to improve the effectiveness of trial execution.

Growing demand for quality data is expected to drive the market growth. Some of the other factors such as increasing demand for personalized drugs, increasing adoption of new technology in clinical research, growing research & development promoting outsourcing and increasing diseases prevalence will drive the market in the forecast period of 2020 to 2027

Complete report is available

For an excellent outcome of Automation Testing report, qualitative and transparent research studies are carried out devotedly for the specific niche. Being a global market research report, it also identifies, analyses, and estimates the emerging trends along with major drivers, challenges and opportunities in the industry and analysis of vendors, geographical regions, types, and applications. An idea about competitive landscape plays very important role in deciding about the improvements required in the product and more. As businesses can achieve thorough insights with this report, they can confidently take decisions about their production and marketing strategies.

The titled segments and sub-section of the market are illuminated below:

By component(Industrial PC, Mass Interconnect, Handler, and Probers),

By Type(memory chip, mixed signal, digital, and others),

By Application(consumer electronics, automotive, aerospace and defense, and medical)

Region Included are:

United States, Europe, China, Japan, Southeast Asia, India & Central & South America

Top Players in the Market are Verizon Communications, IBM Corporation, Aemulus Holdings Bhd (Aemulus), Chroma ATE Inc., Aeroflex Inc., Astronics Corporation, Advantest Corporation, LTX-Credence Corporation (Xcerra Corporation), Teradyne Inc.,

How will the report help new companies to plan their investments in the Automation Testing market?

The Automation Testing market research report classifies the competitive spectrum of this industry in elaborate detail. The study claims that the competitive reach spans the companies of.

The report also mentions about the details such as the overall remuneration, product sales figures, pricing trends, gross margins, etc.

Information about the sales & distribution area alongside the details of the company, such as company overview, buyer portfolio, product specifications, etc., are provided in the study.

Any query? Enquire Here For Discount Or Report Customization:https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-automation-testing-market

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Chapter 2: Executive Summary

Chapter 3: Automation Testing Industry Insights

Chapter 4: Automation Testing Market, By Region

Chapter 5: Company Profile

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

Continued here:
Automation Testing Market is expected to expand at an impressive rate by 2027 with leading Players Marvin Test Solutions Inc. and Danaher Corporation,...

HAMBURG, GERMANY / ACCESSWIRE / September, 14, 2020 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the French-based BIOASTER Technological Research Institute ("BIOASTER") today announced that they have entered into a partnership to advance research for infectious diseases. BIOASTER is a technology and innovation hub located in Lyon, France that has created a new model to address the latest challenges in the microbiology field, including antimicrobial resistance and vaccine safety and efficacy.

The organisations have been working together since the beginning of 2020 and Evotec represents the first global research and development company to locate staff in BIOASTER's premises in Lyon.

Under the terms of the collaboration agreement, the two organisations aim to put forward new research projects against infectious diseases and antimicrobial resistance, potentially creating new therapies and technologies. This collaboration had already started through the European research projects and development consortium ERA4TB (European Regimen Accelerator for Tuberculosis) and GNA NOW (Novel Gram-negative antibiotic now) within the AMR accelerator supported by the Innovative Medicines Initiative IMI2, aimed at reducing resistance to antibiotics and developing new therapeutic solutions.

"BIOASTER is proud to have support from the French and European leaders in diagnostics, vaccines, and animal health, and is pleased to formalise such a partnership with Evotec at the Lyon site. This allows BIOASTER to strengthen its agility and its capacity for technological innovation, in particular on antimicrobial resistance. BIOASTER now has a high-value network of close partners, which covers our four fields of application: antimicrobials, diagnostics, vaccines and microbiota understanding are key for manufacturers and patients alike," said Dr Philippe Archinard, President of IRT BIOASTER.

"The agreement will nurture the research ecosystem of Lyon Metropole and its Biodistrict, and impact on both national and European levels. The fact that Evotec, a company headquartered in Hamburg, Germany, chose to locate its unit dedicated to infectious diseases together with BIOASTER in the Biodistrict Lyon, reinforces the reputation of this French health ecosystem, while offering a more complete and more powerful technological toolbox to speed up industrialisation of innovations," said Emeline Baume, first vice president of Lyon Metropole.

"We are very glad to be partnering with BIOASTER, bringing Evotec's proven global resources for anti-infective research and drug development to Lyon," said Dr Werner Lanthaler, Chief Executive Officer of Evotec. "Both Evotec and BIOASTER have made a long-term commitment to tackle the challenge of antimicrobial resistance and we are confident that together we will be able to efficiently drive forward the progress in this field with high and rising unmet medical need."

The two entities gather more than 120 researchers in total, share the same advanced infrastructures, including five BSL3 laboratories, with easy access to diverse equipments: this co-location creates a new pole of attraction, particularly suited to the expectations of industrials to accelerate and de-risk their product developments in infectious diseases.

ABOUT BIOASTER TECHNOLOGICAL RESEARCH INSTITUTE

Created in 2012, following the French initiative of Technological Research Institutes, BIOASTER is a non-for-profit foundation developing a unique technological and innovative model to support the latest challenges in microbiology. In particular, BIOASTER uses and develops high value technological innovations that accelerate development of medical solutions for populations and personalized medicine.

The aim of BIOASTER is to bring together academic, industry and its capacities and specific knowledge to develop and execute high impact collaborative projects requiring industry compatible innovative technologies.

Key figures:

* 4 fields of expertise: antimicrobials, diagnostics, microbiota, vaccines* BSL2 & BSL3 laboratories in Lyon and Paris* 100+ employees, including 80% of scientific experts, 17 nationalities* 66+ collaborative projects, involving 27 private partners, 29 public partners.

http://www.bioaster.org

ABOUT EVOTEC SE

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,300 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to http://www.evotec.com and follow us on Twitter @Evotec.

FORWARD-LOOKING STATEMENTS

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

SOURCE: Evotec AG via EQS Newswire

View source version on accesswire.com:https://www.accesswire.com/605953/Evotec-and-BIOASTER-Partner-to-Build-a-Technology-and-Innovation-HUB-in-Lyon

Continue reading here:
Evotec and BIOASTER Partner to Build a Technology and Innovation HUB in Lyon - BioSpace

The urinalysis market is projected to reach USD 4.6 billion by 2024 from USD 3.2 billion in 2019, at a CAGR of 7.6% from 2019 to 2024.

Integrated systems for urinalysis and the emerging economies are expected to provide a wide range of growth opportunities for players in the market which is driven by growing incidences of UTI and other kidney diseases.

According to the latest research report [146 Pages Report] The global urinalysis market is projected to reach USD 4.6 billion by 2024 from USD 3.2 billion in 2019, at a CAGR of 7.6% from 2019 to 2024.

Urinalysis Market by Product (Dipsticks, Pregnancy & Fertility Kits, Reagents, Disposables, Automated, Semi-automated, PoC Analyzers), Application (UTI, Diabetes, Pregnancy), End User (Hospital, Labs, Homecare) & Test Type - Global Forecast to 2024

Download a PDF Brochure @ http://www.marketsandmarkets.com/pdfdown=153479294

What drive the Urinalysis Systems Market?

However, the availability of government funding for life science research, drug development regulations, advances in live cell imaging techniques, growth in the biotechnology and pharmaceutical industries, and the rising incidence of cancer.

The Urinalysis Systems market, based on product type, is segmented into consumables and instruments. The consumables segment dominated this market in 2019.

The urinalysis consumables market is segmented into pregnancy & fertility kits, dipsticks, reagents, and disposables. Pregnancy and fertility kits accounted for the largest share of Urinalysis Systems market in 2019.

These kits have witnessed wide adoption amongst end users across the globe owing to their cost-effectiveness and ease of use.

North America to grow at the highest rate during the forecast period (20192024)

The Urinalysis Systems market in North America is expected to grow at a rapid pace in the coming years.

There has been a tremendous increase in the use of urine analysis and has become a part of any general health check up in the past decade. Increasing research activities in the field of urinalysis and growing awareness of personalized medicine have also resulted in the establishment point of care systems.

Automated devices have also been installed in the large hospitals and laboratories.

Request a Sample Pages @ http://www.marketsandmarkets.com/request=153479294

Recent developments:

This email address is being protected from spambots. You need JavaScript enabled to view it.

Link:
Urinalysis Market | North America to grow at the highest rate during the forecast period (20192024) - WhaTech

The pursuit of new medical treatments often hinges on the balance between the efficacy of the drug and the adverse effects it causes. A key part of that balance is deciding on recommended dosing for a given treatment.

Opioids provide an excellent example of the challenge in maintaining that balance and the risks of non-ideal dosing. 20% of patients experiencing pain are prescribed opioids even though the recommended dose of the drugs will cause 50-80% of patients to experience some serious adverse effects. OxyContins standard dose was discovered to wear off early for many leading some users to take dangerously high amounts.

The problem with dosing is well known in the medical community. For instance, some doctors have advocated using much lower doses than recommended on product monographs in non-severe situations. Similarly, for cancer treatments, high dosing levels are being challenged as advanced treatments like immunotherapy gain popularity.

Problems exist on the other end of the spectrum as well. Nonsteroidal Anti-inflammatory Drugs NSAIDs are a common over-the-counter pain treatment and a 2018 study found that 15% of people took dangerously high amounts to reduce their pain. One explanation for the overuse was the lack of sufficient pain relief provided by the recommended dose. Taken in large quantities, the drugs can cause serious stomach issues.

A major reason for these dosing issues is that decisions are made on a statistical basis for large sample patient populations. The variability of these populations, including differences in height, weight, and ethnic background, make it unlikely that recommended doses will be ideal for everyone. Fortunately, as medicine is opening to non-pharmaceutical options, personalization is becoming easier. As a result, a new paradigm for dosing is emerging.

Personalized MedicinePersonalized medicine, a medical approach that optimizes both response and safety for individual patients, provides an alternative model to dosing that considers individual patient needs. For instance, 5% of the population do not get pain relief from codeine while others have it stay in the body too long due to their genetics. The ability to identify a patients genetics can help doctors make dosing decisions.

Unfortunately, genetics-based personalized medicine is costly and complicated for various reasons such as increased training and adapting electronic health records. An alternative approach is to allow patients to try different doses in cooperation with their physicians to discover the ideal balance. With pharmaceuticals though, this can mean delaying an effective treatment or exposing patients to adverse reactions and drug interactions.

Personalization Through DevicesOne solution that is gaining popularity is to turn to non-pharmaceutical medical devices when possible. These devices allow for a far greater range of safe treatment options that a patient can adjust even during a single treatment. For example, several medical devices using electrical neuromodulation have been developed to treat pain, spinal injuries, epilepsy, migraine, and other conditions. The devices stimulate nerves through electrical pulses delivered at different intensities to treat the given problem. Essentially, these intensities are the doses, but because they are not interacting with the body as pharmaceuticals do, they allow for a wider range of treatment options.

More than just a new technological solution, the possibility presented by these and similar medical devices is significant. User-controlled customization of the intensity of each treatment will both engage users and create a far higher chance of finding an ideal dose for each patient. Chronic pain patients, who may be more reliant on frequent use of pharmaceuticals, could especially benefit as they are most susceptible to having to limit dosing even if it makes the therapy less successful.

Back to the NSAID issue mentioned above, it is very easy for patients to take a third Advil pill for pain relief without sensing the danger of overdosing. With devices delivering electronic stimulation, the feeling of intensity is an immediate sensational signal that places a natural limit on the dose, without any serious long-term negative effects. Patients can trust that they can take a high yet tolerable dose safely. If their issue is still not solved, they can go back to their doctor to try different treatments.

ConclusionPersonalizing dosing is the future of treatment development. Allowing for individual patients to select their ideal dose will improve outcomes and reduce adverse events. Some aspects of personalization, such as seamlessly incorporating a patients genetics into dosing decisions, is still too costly to apply widely. However, we can create new treatments that give patients more control and safe choices, such as those provided by medical devices.

Pains ubiquity and its ability to be treated through medical devices make it a perfect target for this new approach. As with any new paradigm though, we need to educate patients and medical professionals about this new possibility. Furthermore, we need to lower costs and improve insurance processes to make sure that they are available to everyone.

If we do so, we will not only support patients (or customize treatment), but we will also improve outcomes and save money by avoiding adverse events.

Photo: Olena Agapova, Getty Images

See the original post:
Moving beyond one-dose-fits-all: How medtech and personalized dosing can improve outcomes - MedCity News

BIRMINGHAM, Ala. (PRWEB) September 14, 2020

CerFlux, Inc., creators of advanced personalized medicine technology for specifically matching treatments to each cancer patients tumor before treatment, announced today the receipt of a $249,148 National Cancer Institute R43 grant to help fund continuing development of its low-cost, rapid Personalized Oncology Efficacy Test (POET) for Pancreatic Ductal Adenocarcinoma.

What makes this endeavor particularly noteworthy is that it will not only expand the body of knowledge but, if successful, transform cancer treatment around the world. Today, less than 3% of funded research makes such a leap across the valley of death from new knowledge to innovation.

Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers, with a less than 9% five-year survival rate. Without advances in technology like POET, the death rate from PDAC is estimated to increase to 60,000 deaths/year within the next 10 years. What makes PDAC particularly insidious is that a large number of patients arent diagnosed until the disease is at an advanced stage. While research and discovery are making new treatment options available, the lack of tools to quickly select the right treatment for each patient on a personalized basis creates a frustrating paradox in clinical decision-making. This is because every tumor is unique in its makeup and its response to treatment.

Without personalized predictive tools like POET, treatment is based on generalized parameters such as age, disease stage, etc. often leading to a mismatch between treatments and tumors. Consequently, about 75% of patients nearly 3 out of 4 have to endure first line chemotherapy that turns out to be ineffective because the treatment regimen did not match the patients tumor, imposing a substantial physical, emotional, and financial burden.

CerFlux POET addresses this critical, urgent, and unmet need for accessible and affordable predictive technologies that identify optimal therapy regimens and strategically eliminate ineffective options.

Our goal for this phase of the project is to identify best practices for using POET in personalized therapy and to measure the degree to which the effectiveness of the treatment observed in POET approximates the response in the corresponding patient. The idea is to not only predict which ones will be effective but also identify those which would be potentially ineffective for that specific patient to reduce the pain and time, explains CerFlux CEO Dr. Karim Budhwani.

This endeavor is further enhanced by a commercial-academic collaboration between CerFlux, Inc. and the James Comprehensive Cancer Center at the Ohio State University. This NCI funded project will build on recent work by the CerFlux team including a patented (US 10,114,010B1) biomimetic in vitro platform for pharmacological transport and pancreatic microtissue tumor models.

Dr. Allan Tsung, Director of the Gastrointestinal Disease Specific Research Group, adds, "I truly believe that the best cancer care is multidisciplinary care and similarly, advances in cancer research requires team science with multidisciplinary collaboration. The most innovative answers to problems are when you bring together ideas from different fields. Our team working together with CerFlux, Inc., embraces the belief at the Ohio State James Comprehensive Cancer Center that 'there is no routine cancer'. With advances in technology like POET, we strive to offer groundbreaking, personalized treatment options for all our patients battling cancer."

Predictive technologies like POET that match each patient with the right treatment regimen BEFORE treatment is administered will transform pancreatic cancer treatment in the near-term and make a difference in the lives of patients and their families, as well as providers around the world.

About CerFlux, Inc.CerFlux, Inc., a Birmingham, Alabama, based biotech company, is creating advanced, personalized medicine solutions to rapidly identify the most effective cancer treatments for each patient on an individualized basis. While breakthroughs in biopharma discovery are helping to produce a library of treatment options, many new therapeutics are becoming more specialized and therefore effective for smaller populations. This underscores an even greater need for matching treatments to tumors on an individualized basis; ironically, cancer is a ubiquitous rare disease. Our goal is to build solutions that quickly and clearly separate optimal from ineffective options, so clinical teams can successfully treat the disease thereby improving treatment outcomes and quality of life for cancer patients.

Additional InformationTo request collateral materials for publication or to schedule interviews with principals from CerFlux, Inc., please contact Rebecca Dobrinski at rsd@CerFlux.com or 205.335.3434 for availability.

Share article on social media or email:

Read this article:
CERFLUX Announces National Cancer Institute Award - PR Web

A policy initiative was set up 5 years ago with the goal of spreading the adoption of a therapeutic strategy to maximize the brain health of every person with MS. The principle idea was that MS should be treated as effectively as early as possible, said Gavin Giovannoni, MBBCh, PhD, FCP (Neurol., SA), FRCP, FRCPath, chair of neurology at the Blizard Institute in the Barts and The London School of Medicine and Dentistry at Queen Mary University of London.

This means intervening early and effectively to affect the trajectory of MS over time. Im convinced we are doing this now, he said.

In the predisease-modifying therapy (DMT) era, by age 65, more than 80% of patients with MS needed a walking stick1. However, by the era of low-efficacy DMTs, that proportion was down to 60%, and now, in the high-efficacy era of DMTs, that proportion has fallen further, to 20% to 30% of patients needing a walking stick by the age of 65.

So, theres no doubt that by adopting this early, effective treatment approach, we have a major impact on the overall outcome, Giovannoni explained.

However, the challenge remains: how do we determine which patients with MS will respond to treatments? If there are 100 patients, its not clear who will or wont respond to therapy, and the only real option is to use statistical modeling.

Providers have to decide if they want to gamble on low- or high-efficacy therapies when they initiate treatment. Should they start with low-efficacy and move through the tiers or go right to the top tier from the outset?

Research has shown that early access to high-efficacy DMTs results in better outcomes. For fingolimod, natalizumab, and alemtuzumab the response rates are much higher, and they are associated with a lower risk of conversion to secondary progressive MS compared with therapies like interferon beta or glatiramer acetate.2 In addition, patients who started on high-efficacy therapies within 2 years of disease onset had less disability after 6 to 10 years than patients who started high-efficacy therapy later in the disease course.3

Theres little doubt in my mindearly access is whats important, Giovannoni said. Early access not late access.

However, treatment is not only about efficacypatients are going to be exposed to serious adverse events on these therapies. This is when patient choice becomes important. Providers will need to take into account issues like family planning and pregnancy when personalizing treatments.

Thats why safety comes into it, Giovannoni said. We always worry about the serious adverse event when we are customizing treatment strategies for patients with multiple sclerosis.

At baseline, the provider needs to look for ways to de-risk the high-efficacy DMTs to make them more palatable for patients to try as a first-line therapy.

Understanding the individuals disease is crucial, including profiling the patient in terms of understanding their risk aversion, adherence, comorbidities, and other factors before customizing treatment However, once that is done, it must be layered onto the health system and economic factors, he pointed out.

So, there is not a simple solution to the customized medicine in relation to our disease-modifying therapy, Giovannoni said.

Subgroup analyses to understand response rates

Predicting a better response to treatments is very important in MS now that there are multiple treatment options to choose from, said Maria Pia Sormani, professor of biostatistics at the University of Genoa, Italy.

However, it is not easy to define response to treatment in MS. For instance, in solid tumors, a reduction in the tumor mass after chemotherapy is defined as a response to treatment because there is no spontaneous mass reduction without treatment. In relapsing-remitting MS, simply having no relapses after an immunomodulatory drug cannot be defined as having a response to treatment, because in the disease, patients can have stable disease course even without treatment.

A subgroup analysis can help better understand patients who are responders to therapy, she explained. One study of cladribine tablets showed that while the overall risk reduction versus placebo was 50%, there were differences in response depending on disease activity.4 In patients with high disease activity, the probability of disease progression was reduced by more than 80% among patients who took cladribine; the reduction was less than 20% in patients without high disease activity.

Sometimes, when many subgroups are tested, researchers will find by chance that some subgroups have a higher response to treatment, but that finding might not be confirmed in a follow-up study, Sormani noted.

Another analysis showed that in the DEFINE study,5 patients with no prior MS treatment had a relapse risk reduction of 67% when treated with oral BG-12 (dimethyl fumarate), but in the CONFIRM study,6 the opposite was true: the reduction was only 36% in patients with no MS treatment, and the risk reduction was larger in patients who had previous treatment (54%).

A new approach that Sormani and her colleagues crafted would create a personalized profile of patients who respond better using a patient-specific continuous score.7 They applied the analysis to 3 trials: ALLEGRO was used to define the score; BRAVO was used to test the score; and CONCERTO was used to externally validate the findings.

The score was able to define responders and nonresponders, and Sormani provided an example of how it might be applied in clinical practice. First instance, take a patient with MS with 1 relapse in the previous year, 1 gadolinium-enhancing lesion on the baseline scan, and a normalized brain volume of 1600 cm3:

In conclusion, Sormani noted that there are now statistical techniques based on post-hoc analyses of clinical trials that can help identify which patients will benefit the most from which treatments in order to choose the best MS therapy for them.

We must try to push on pharmaceutical companies to allow re-analysis of their clinical trials to identify subgroup responders to every drug, she said.

References

1. Capra R, Cordioli C, Rasia S, Gallo F, Signori A, Sormani MP. Assessing long-term prognosis improvement as a consequence of treatment pattern changes in MS. Mult Scler. 2017;23(13):1757-1761. doi:10.1177/1352458516687402

2. Brown JWL, Coles A, Horakova D, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA. 2019;321(2):175-187. doi:10.1001/jama.2018.20588

3. He A, Merkel B, Brown JWL, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19(4):307-316. doi:10.1016/S1474-4422(20)30067-3

4. Giovannoni G, Soelberg Sorensen P, Cook S, et al. Efficacy of cladribine tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: a post hoc analysis of the CLARITY study. Mult Scler. 2019;25(6):819-827. doi:10.1177/1352458518771875

5. Bar-Or A, Gold R, Kappos L, et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol. 2013;260(9):2297-305. doi:10.1007/s00415-013-6954-7

6. Hutchinson M, Fox RJ, Miller DH, et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol. 2013;260(9):2286-96. doi:10.1007/s00415-013-6968-1

7. Pellegrini F, Copetti M, Bovis F, et al. A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis. Mult Scler. 2020;26(9):1064-1073. doi:10.1177/1352458519849513

More:
Choosing the Right MS Treatment by Customizing Therapy to the Individual - AJMC.com Managed Markets Network

NEW YORK, Sept. 14, 2020 /PRNewswire/ --PulsePoint, the leading technology company using real-time data to accelerate health outcomes, is set to host their second bi-annual Digital Health Forum in October. Themed "The Future was Today," the event is designed around discussions aiming to disentangle many of the challenges within healthcare and rewrite an ideal vision that capitalizes on the opportunities technology and health data present.

PulsePoint prides itself in being a forward moving company, a sentiment captured in its corporate tagline, 'Leading Health Forward'. With this event, the company is leaning into the change we're currently going through and enlisting other forward-oriented minds to collectively re-envision how we use data and technology to help people make better health decisions.

Many big minds are trying to work through the current business challenges created by the pandemic. PulsePoint wants to look beyond, to address key issues facing healthcare, specifically around what health data will look like in five years, how rules are being re-written and what new behaviors are being formed. While no one can see that far ahead, PulsePoint is crafting the event to stimulate an exchange of ideas and creative thinking, with the ultimate goal of making us all more purposeful in charting a smart, productive and compassionate way forward.

The forum will feature an eclectic mix of multidisciplinary speakers including doctors, health policy officials, futurists, disruptors, technologists, journalists, non-profits, media personalities, and even teens representing the voices of tomorrow. Key headliners include Dr. Scott Gottlieb, former commissioner of the FDA, Bob Garfield, co-host of On the Media and Dr. Amy Zalman, CEO of Prescient and Professor of Foresight at Georgetown University.

PulsePoint's last Digital Health Forum, at Lincoln Center in 2018, focused on 'Radical Health Personalization' and explored topics such as consumer privacy, health data security, personalized medicine and humanitarianism in digital health.

"PulsePoint's Digital Health Forum is a foundational event for the health industry as data and technology intercepts with the huge transformational shift we are seeing in the market. The year 2020 will be viewed as a point in time when the health industry fundamentally embraced digital technology and finally turned their backs on the analog world that has slowed down its progress for so many years," said PulsePoint CEO, Sloan Gaon. "We're bringing experts together from different parts of health, technology and media to dig into what's new, what's next and what's actionable."

The event will be held virtually on October 6th. Register at TheFutureWasToday.com

About PulsePoint

We are a technology company using real time data to transform healthcare. Through machine learning and programmatic automation, we interpret the hard-to-read signals of the health journey to understand the connection points between relevance and engagement. We do this by unifying real-time Digital Determinants of Health, offline and clinical data to create a unique and precise view of health audiences that refines, improves and increases its view over time. Visit http://www.pulsepoint.com for more about the company's technology and award winning culture.

Contact: Maria Simeone [emailprotected]

SOURCE PulsePoint

See the article here:
PulsePoint's Digital Health Forum 'The Future was Today' to Explore the Rapid Transformational Change Occurring Within Healthcare - PRNewswire

SAN FRANCISCO, Sept. 14, 2020 /PRNewswire/ -- The global artificial intelligence in drug discovery marketsize is expected to reach USD 3.5 billion by 2027, expanding at a CAGR of 28.8%, according to a new report by Grand View Research, Inc. The growing adoption of artificial intelligence (AI) platforms aimed at reducing the overall cost associated with drug discovery and to enhance results is expected to propel the demand for these platforms in the pharma market.

Key suggestions from the report:

Read 80 page research report with ToC on "Artificial Intelligence In Drug Discovery Market Size, Share & Trends Analysis Report By Therapeutic Area (Oncology, Cardiovascular Disease, Metabolic Diseases), By Application, By Region, And Segment Forecasts, 2020 - 2027'' at: https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-drug-discovery-market

Based on the application, the drug optimization and repurposing segment accounted for the largest revenue share in 2019. AI platforms help in identifying alternative applications for existing medicines. This can help pharma companies diversify their portfolio of offerings and assist in producing alternative therapies through minor alterations in the pharmaceutical product. Furthermore, AI platforms also enable researchers to identify the toxic effects of the medicine on the body and thus reduce the chances of adverse effects.

In 2019, oncology application accounted for the largest share whereas, the infectious disease application segment is expected to emerge as the fastest-growing application segment over the forecast period. Artificial intelligence already plays a vital role in the early detection of cancer. Furthermore, as treatments for cancer may vary for each patient, personalized medicine has proven to be an effective alternative.

North America dominated the market with a revenue share of 59.4% in 2019 owing to the increasing adoption of artificial intelligence and the presence of a large number of market players. Asia Pacific is expected to emerge as the fastest-growing region in the market over the forecast period. The growing adoption of new technology in India and China for new drug development and a focus towards boosting pharmaceutical capacities within the countries is expected to drive the market in the region.

Grand View Research has segmented the global artificial intelligence in drug discovery market based on application, therapeutic area, and region:

List of Key Players of Artificial Intelligence In Drug Discovery Market

Find more research reports on Healthcare IT Industry, by Grand View Research:

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:Sherry JamesCorporate Sales Specialist, USAGrand View Research, Inc.Phone: +1-415-349-0058Toll Free: 1-888-202-9519Email: [emailprotected]Web: https://www.grandviewresearch.comFollow Us: LinkedIn| Twitter

SOURCE Grand View Research, Inc.

Continued here:
Artificial Intelligence In Drug Discovery Market Size Worth $3.5 Billion By 2027: Grand View Research, Inc. - PRNewswire

Robots welding at the assembly line of the French car maker Peugeot/Citroen in Brazil. Artificial intelligence offers a chance for the Latin America's economies to leapfrog to greater innovation and economic progress.

Photo: Antonio Scorza/AFP/ Getty Images

Share this article

E-commerce firms have faced a conundrum in Latin America: How can they deliver packages in a region where 25% of urban populations live in informal, squatterneighborhoods with no addresses?

Enter Chazki, a logistics startup from Peru, which partnered with Arequipas Universidad San Pablo to build an artificial intelligence robot to generate new postal maps across the country. The company has now expanded to Argentina, Mexico and Chile, introducing remote communities and city outskirts to online deliveries.

Thats just one example of how machine learning is bringing unique Latin American solutions to unique Latin American challenges. Artificial intelligence and its correlated technologies could prove a major boon to the regions public and private sectors. In turn, its policymakers and business leaders have to better prepare to take full advantage while warding off potential downsides.

Latin America has long been the victim of low productivity and the COVID-19 pandemic is predictably making matters worse. Now, artificial intelligence is a chance for the regions economies to leapfrog to greater innovation and economic progress. Research suggests that AI will add a full percentage point of GDP to five of South Americas biggest economies Argentina, Brazil, Chile, Colombia and Peru by 2035.

Artificial intelligence could play transformative roles in Latin America for just about every sector, according to the Inter-American Development Bank (IADB). That means using AI to predict trade negotiation outcomes, commodity prices and consumer trends, or developing algorithms for use in factories, personalized medicine, infrastructure prototyping, autonomous transportation and energy consumption.

AIs applications in Latin America are already becoming reality. Argentinian Banco Galicia, Colombian airline Avianca, and Brazilian online shopping platform Shop Fcil have all adopted chatbots as virtual customer service assistance to help people. Chiles The Not Company developed an algorithm that analyzes animal-based food products and a database of 400,000 plants to generate recipes for vegan alternatives, and Perus National University of Engineering built machines to autonomously detect dangerous gases.

Expect the trend to continue in the near future. An MIT global survey of senior business executives worldwide found that, by the end of 2019, 79% of companies in Latin America had launched AI programs. The results have been positive; fewer than 2% of respondents reported that the initiatives made lower-than expected returns.

Another key factor is public acceptance of AI and automation. Thus far, Latin Americans are ahead of the curve in embracing the future, with another recent poll showing that 83% of Brazilian consumers said they would trust banking advice entirely generated by a computer, compared to a global average of 71%.

In a region that suffers from endemic corruption, pervasive violence, weak institutions and challenging socioeconomic conditions, governments, policymakers and organizations can use AI to tackle critical issues in the region, including food security, smart cities, natural resources and unemployment.

In Argentina, for example, artificial intelligence is being used to predict and prepare for teenage pregnancy and school dropout, as well as to outline unseen business opportunities in city neighborhoods. In Colombia and Uruguay, software has been developed to predict where crimes are likely to occur. In Brazil, the University of So Paulo is developing machine-learning technology that will rapidly assess the likelihood that patients have dengue fever, Zika or chikungunya when they arrive at a medical center.

At a time when public support for democracy in Latin America is flailing, AI could help come to the rescue. Congressional bodies across the region could use AI to boost the transparency and input of the legislative process. Indeed, the Hacker Laboratory, an innovation lab within Brazils Chamber of Deputies, is using AI platforms to facilitate interactions between lawmakers and citizens.

AI is not risk-free, of course. Elon Musk called AI humanitys biggest existential threat, and Stephen Hawking said it could spell the end of the human race.

Apocalyptic scenarios aside, the immediate danger of AI in Latin America is unemployment and inequality. The Inter-American Development Bank (IADB) warned in a 2018 study that between 36% and 43% of jobs could be lost due to artificial intelligence as a result of automatization. Indeed, Latin Americas governments must be prepared to set up guardrails and implement best practices for the implementation of AI.

Several governments in the region have already announced AI public policy plans. Mexico was one of the first 10 countries in the world to create a national AI strategy. Meanwhile, Brazil launched anational Internet of Things plan, which includes the countrys commitment to a network of AI laboratories across strategic areas including cybersecurity and defense. Chile is coordinating with civil society groups and experts to adopt its own AI plan.

Move aside, Mercosur! Governments in Latin America might also find that machine learning strengthens regional ties. That means harnessing AI to crunch data on trade flows and rules, find areas of consensus in multilateral negotiations, or create algorithms for regional trade. After all, AI models have a 300% greater predictive capacity than traditional econometric models, according to the Inter-American Development Bank.

Beyond competing national plans for AI, Latin American leaders should be drafting a strategy that is specific to its region much like the European Union is doing. A key takeaway from the recent UNESCO Regional Forum on AI in Latin America and the Caribbean was that the technology must develop with respect to universally recognized human rights and values.

In 2021, artificial intelligence could generate almost $3 trillion in business value and 6.2 billion hours of productivity worldwide. Latin America is rightfully jumping onto the bandwagon and has the potential to lead the parade in some areas.

To make full use of what could be a transformational productivity revolution for the region, government and business leaders must pump more resources into technology planning and education. The implementation of AI must improve, not accelerate, the regions inequity.

Read more:
Latin America's Growing Artificial Intelligence Wave BRINK News and Insights on Global Risk - BRINK

DGAP-News: Evotec SE / Key word(s): Miscellaneous14.09.2020 / 07:30 The issuer is solely responsible for the content of this announcement.

Hamburg, Germany, 14 September, 2020: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the French-based BIOASTER Technological Research Institute ("BIOASTER") today announced that they have entered into a partnership to advance research for infectious diseases. BIOASTER is a technology and innovation hub located in Lyon, France that has created a new model to address the latest challenges in the microbiology field, including antimicrobial resistance and vaccine safety and efficacy.

The organisations have been working together since the beginning of 2020 and Evotec represents the first global research and development company to locate staff in BIOASTER's premises in Lyon.

Under the terms of the collaboration agreement, the two organisations aim to put forward new research projects against infectious diseases and antimicrobial resistance, potentially creating new therapies and technologies. This collaboration had already started through the European research projects and development consortium ERA4TB (European Regimen Accelerator for Tuberculosis) and GNA NOW (Novel Gram-negative antibiotic now) within the AMR accelerator supported by the Innovative Medicines Initiative IMI2, aimed at reducing resistance to antibiotics and developing new therapeutic solutions.

"BIOASTER is proud to have support from the French and European leaders in diagnostics, vaccines, and animal health, and is pleased to formalise such a partnership with Evotec at the Lyon site. This allows BIOASTER to strengthen its agility and its capacity for technological innovation, in particular on antimicrobial resistance. BIOASTER now has a high-value network of close partners, which covers our four fields of application: antimicrobials, diagnostics, vaccines and microbiota understanding are key for manufacturers and patients alike," said Dr Philippe Archinard, President of IRT BIOASTER.

"The agreement will nurture the research ecosystem of Lyon Metropole and its Biodistrict, and impact on both national and European levels. The fact that Evotec, a company headquartered in Hamburg, Germany, chose to locate its unit dedicated to infectious diseases together with BIOASTER in the Biodistrict Lyon, reinforces the reputation of this French health ecosystem, while offering a more complete and more powerful technological toolbox to speed up industrialisation of innovations," said Emeline Baume, first vice president of Lyon Metropole.

"We are very glad to be partnering with BIOASTER, bringing Evotec's proven global resources for anti-infective research and drug development to Lyon," said Dr Werner Lanthaler, Chief Executive Officer of Evotec. "Both Evotec and BIOASTER have made a long-term commitment to tackle the challenge of antimicrobial resistance and we are confident that together we will be able to efficiently drive forward the progress in this field with high and rising unmet medical need."

The two entities gather more than 120 researchers in total, share the same advanced infrastructures, including five BSL3 laboratories, with easy access to diverse equipments: this co-location creates a new pole of attraction, particularly suited to the expectations of industrials to accelerate and de-risk their product developments in infectious diseases.

ABOUT BIOASTER TECHNOLOGICAL RESEARCH INSTITUTECreated in 2012, following the French initiative of Technological Research Institutes, BIOASTER is a non-for-profit foundation developing a unique technological and innovative model to support the latest challenges in microbiology. In particular, BIOASTER uses and develops high value technological innovations that accelerate development of medical solutions for populations and personalized medicine.The aim of BIOASTER is to bring together academic, industry and its capacities and specific knowledge to develop and execute high impact collaborative projects requiring industry compatible innovative technologies.Key figures:* 4 fields of expertise: antimicrobials, diagnostics, microbiota, vaccines* BSL2 & BSL3 laboratories in Lyon and Paris* 100+ employees, including 80% of scientific experts, 17 nationalities* 66+ collaborative projects, involving 27 private partners, 29 public partners.www.bioaster.org

ABOUT EVOTEC SEEvotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,300 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to http://www.evotec.com and follow us on Twitter @Evotec.

FORWARD-LOOKING STATEMENTSInformation set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

14.09.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at http://www.dgap.de

Read more here:
EVOTEC AND BIOASTER PARTNER TO BUILD A TECHNOLOGY AND INNOVATION HUB IN LYON - PharmiWeb.com

Despite not being able to attend conferences live, there are some advantages to a virtual conference.

Personalized medicine might be a realistic target in many specialties in the next decade, including pulmonology.

Recently, in a paper presented at theEuropean Respiratory Society International Congress 2020 (ERS 2020), researchers presented data showing adiponectin and leptin were significantly different between men and women, with higher levels found in female patients.

Lars L. Andersson, PhD, Karolinska Institute, said 1 of the objectives of the study was to get closer to personalized medicine in an effort to derive what treatments could be most effective in individual patients.

Andersson explained in an interview with HCPLive, the new study gives researchers a better understanding of the impact of sex and age on circulating adipokines.

The study included 55 patients with mild to moderate asthma, 72 patients with severe asthma, and 41 patients with COPD. Overall, the researchers found both adiponectin and leptin were highly affected by body mass index (BMI), another datapoint for personalized medicine.

In a subgroup analysis, they found the difference in adiponectin between women and men was smaller in lean patients, while the difference in leptin was smaller in obese patients.

While the study was important, in a normal year Andersson would be able to present it live to his colleagues. However, with the coronavirus disease 2019 (COVID-19) pandemic bringing conferences virtual Andersson was forced to adjust.

However, Andersson said the virtual format has some benefits.

Read the original:
Lars Andersson, PhD: The Future of Personalized Medicine for Asthma - MD Magazine

The proteomics market is segmented on the basis of proteomics instrumentation technology such as protein microarray (biochips, microarray instruments), spectroscopy (Mass and NMR), X-ray crystallography, chromatography, electrophoresis, proteomics reagents, proteomics services (analytical lab services, protein identification, extraction, sequencing, data analysis, maintaining bioinformatics data bases). The market is driven by growing need of personalized medicines, new discoveries in the field of genomics, rise in funds for proteomics based research, growing research and development expenditure, advancement in technologies, new techniques, high output, high resolutions achiness and instruments have been developed, availability of private funds and rise in the Asian markets like China and Japan.

The Final Report will cover the impact analysis of COVID-19 on this industry (Global and Regional Market).

Request To Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10233569

The top 10 companies own 40 to 50 percent of the market. Proteomic instrumentation market is dominated by proteomic microarray, accounting for around 50% of the revenue followed by spectroscopy techniques. Proteomic reagents market is dominated by immunoassays.

The market is restrained by various factors such as: success ratio of the researches is not very high, limitations of personalized medicines and lengthy regulatory approval process, reduction in funds by the US government, which owes 40% of this market, highly expensive medicines, which are 1000 fold costlier than the normal medicines present in the market and research and market is limited to a few developed nations only.

Major opportunities for the market lie in the Asian markets where contract research organizations are on a rise. Proteomics is science with broad applications in the field of therapeutics and diagnostics. Growing R&D and emergence of new players will create more market opportunities. Major players in the proteomics market are Thermo Fischer scientific corporation, Agilent technologies, Luminex corporation, Sigma-Aldrich corporation, Danaher corporation, Bio-Rad corporation, Waters corporation, PerkinElmer, Affymetrix and others.

The Final Report will cover the impact analysis of COVID-19 on this industry (Global and Regional Market).

Request To Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10233569

Companies profiled

1. Genzyme Corporation2. Thermo Fischer scientific corporation3. Becton Dickinson and Co4. BG medicine5. Agilent technologies6. Luminex corporation7. Sigma-Aldrich corporation8. Danaher corporation9. Anaspec Inc10. Asterand PLC11. Applied biosystems Inc12. Bayer technology13. Bio-Rad corporation14. Waters corporation15. PerkinElmer16. Affymetrix17. GE healthcare18. Genesystems Inc19. Activx Biosciences Inc20. Amgen Inc21. Beckman coulter22. Biacore International AB23. Biocarta Inc24. Bruker biosciences25. Caliper Lifesciences26. Cellzome AG27. Commonwealth biotechnologies28. Digilab biovision GmBH29. Dionex Corp30. Dualsystems biotech AG

This Research Report covers

1. Historical data2. Revenue forecasts, growth rates and CAGR upto 20283. Industry Analysis4. Competitive Analysis5. Key geographic growth data6. In-depth profiling of companies

Request for Complete Report:https://www.kennethresearch.com/sample-request-10233569

Key Answers Captured in Report?

About Kenneth Research:

Kenneth Research provides market research reports to different individuals, industries, associations, and organizations with the aim of helping them to take prominent decisions. Our research library comprises more than 10,000 research reports provided by more than 15 market research publishers across different industries. Our collection of market research solutions covers both the macro level as well as micro-level categories with relevant and suitable market research titles. As a global market research reselling firm, Kenneth Research provides a significant analysis of various markets with pure business intelligence and consulting services on different industries across the globe. In addition to that, our internal research team always keeps a track of the international and domestic market for any economic changes impacting the products demand, growth, and opportunities for new and existing players.

Updated Research Report Available @Kenneth Research with impact analysis of COVID-19

Geospatial Imagery Analytics MarketNetwork Access Control MarketVisitor Management System MarketPenetration Testing MarketPower Distribution Unit (PDU) Market

See the original post:
Impact Analysis of COVID-19 on Proteomics Market Outlook 2020-2028 by Emerging Global Trends, Leading Companies, Future Growth, Revenue, and Demand...

The global cell surface markers market is valued at an estimated USD 520 million in 2018 and is projected to reach USD 769 million by 2023, at a CAGR of 8.1%

Factors such as the increasing funding for life sciences research, high global prevalence of cancer, and growth in stem cell and neurobiology research are expected to drive the growth of this market in the coming years.

[140 Pages Report] The cell surface markers market is valued at an estimated USD 520 million in 2018 and is projected to reach USD 769 million by 2023, at a CAGR of 8.1% during the forecast period.

Cell Surface Markers Market by Product (Antibody, PCR Array), Source (Mice, Rat), Cell Type (T cells, B cells, NK cell), Application (Research (Stem Cell, Immunology), Clinical (Oncology, Hematology)), and End User (Hospitals) - Global Forecast to 2023

What drives the Market?

The increasing number of R&D activities and the growing use of cell surface markers in personalized medicine and drug discovery & development.

Download a PDF Brochure @ http://www.marketsandmarkets.com/pdfdown=216278622

North America is expected to be the largest regional market for cell surface markers

Market growth in North America, the largest regional market for cell surface markers, is primarily driven by the increasing number of R&D activities and the growing use of cell surface markers in personalized medicine and drug discovery & development. However, the market in Asia is estimated to grow at the highest CAGR during the forecast period.

The high growth of the Asian market can be attributed to the increasing number of life sciences research activities and government initiatives to boost the biotechnology and pharmaceutical industries in several Asian countries.

Key Market Players

The cell surface markers market is highly fragmented in nature, with several big as well as emerging players. Prominent players in this market include Thermo Fisher Scientific (US), QIAGEN N.V.

(Netherlands), Becton, Dickinson and Company (US), F. Hoffman-La Roche (Switzerland), Bio-Rad Laboratories (US), Danaher Corporation (US), Abcam (UK), GenScript (China), BioLegend (US), Cell Signaling Technology (US), Merck KGaA (Germany), and Bio-Techne (US).

Abcam is one of the prominent players operating in the cell surface markers market. The strong position of the company in this market can be attributed to its robust product portfolio.

The company has a strong geographical presence in the European and Asia Pacific markets with its manufacturing facilities in the UK, Japan, and China. The company also has significant market presence in the US and Latin America.

Thermo Fisher Scientific is another leading player in the cell surface markers market. The companys strong brand recognition and extensive product portfolio in this market are its key strengths.

To maintain its leading position in the market, the company adopts organic as well as inorganic growth strategies such as acquisitions and expansions.

Request a Sample Pages @ http://www.marketsandmarkets.com/request=216278622

Recent Developments

This email address is being protected from spambots. You need JavaScript enabled to view it.

Continue reading here:
North America is expected to be the largest regional market for Cell Surface Markers - WhaTech

Global microbiome sequencing marketis expected to rise to an estimated value of USD 3455.33 million by 2026, registering a healthy CAGR in the forecast period of 2019-2026. This rise in market value can be attributed to the focus of various researchers on utilization of this technology in the development of personalized medicine and dietary applications.

For the growth of any business, Microbiome Sequencing market research report plays a very important role. You can get an in-depth market analysis with this report to thrive in this competitive environment. Microbiome Sequencing market report is sure to lend a hand in enhancing sales and improving return on investment (ROI). Estimations of CAGR values, market drivers and market restraints helps businesses decide upon several strategies. DBMR team provides you the Microbiome Sequencing market research report with commitment that is promising and the way in which you anticipate. As it is a third-party report, Microbiome Sequencing report is more unprejudiced and hence provides a better picture of what is really happening in the market.

Ask For Complimentary Sample PDF| Request Athttps://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-microbiome-sequencing-market

Few of the major competitors currently working in the global microbiome sequencing market areBIOLOG; Cosmosid Inc; Illumina, Inc.; Metabiomics Corp.; Oxford Nanopore Technologies; BaseClear B.V.; BGI; BioMathematica; Charles River; CoreBiome, Inc.; Clinical-Microbiomics A/S; Diversigen; Eurofins Scientific; LABCYTE INC.; Leucine Rich Bio Pvt Ltd.; Microbiome Insights; MICROBIOME THERAPEUTICS, LLC; Thermo Fisher Scientific Inc.; Molzym GmbH & Co. KG; Norgen Biotek Corp.; Phase Genomics Inc.; QIAGEN; Resphera Biosciences, LLC; Shoreline Biome; StarSEQ GmbH; Viome, Inc.; Zymo Research among others.

Key Developments in the Market:

Market Drivers

Market Restraints

Inquiry For Customize Report With Discount at :https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-microbiome-sequencing-market

Segmentation: Global Microbiome Sequencing Market

By Sequencing Technology

By Component

By Targeted Disease

By Application

By Research Type

By End-User

By Laboratory Type

ByGeography

Get Full Table Of content @ https://www.databridgemarketresearch.com/toc/?dbmr=global-microbiome-sequencing-market

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like Asia, United States, and Europe.

AboutData Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact:Data Bridge Market ResearchTel: +1-888-387-2818Email:Corporatesales@databridgemarketresearch.com

See the article here:
Global Microbiome Sequencing Market By 2027 Emerging Technology, Opportunities, Analysis And Future Threats With Key Players Like Oxford Nanopore...

Neurological Biomarkers Market Research Report is a Proficient and In-Depth Study on the Existing State of Neurological Biomarkers Industry. This Report Focuses on the Major Drivers, Restraints, Opportunities and Threats for Key Players. It also Provides Granular Analysis of Market Share, Segmentation, Revenue Forecasts and Regional Analysis till 2025.

The recent study on Neurological Biomarkers market offers an all-inclusive analysis of this vertical, with emphasis on the growth driving factors as well as facets such as consumption and production. Constraints and potential threats expected to restrain the expansion along with solutions to overcome the challenges are discussed at length. Moreover, insights of the market share along with estimates reflecting the CAGRs of the listed segments are highlighted in the document.

In hindsight of the COVID-19 pandemic, the report investigates the prevalent business strategies employed by leading organizations and offers tactics for stakeholders to adapt to the industry changes over the forecast period.

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/298496

Key pointers from the Neurological Biomarkers market report TOC:

Additional highlights from the Neurological Biomarkers market report:

Reasons to buy the report

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/298496

Read more:
Neurological Biomarkers Market Structure, Industry Inspection, and Forecast 202 - News by aeresearch

While identifying new genetic targets and developing novel drugs is important for the future of non-small cell lung cancer (NSCLC), more emphasis should be put on improving patient access to existing targeted treatments, according to Dr. Nathan A. Pennell.

In an interview with OncLive, CUREs sister publication, Pennell, an associate professor in thedepartment of medicine and director of the lung cancer medical oncology program at theTaussig Cancer Institute of Cleveland Clinic,spoke about current and emerging treatment options in NSCLC, including immunotherapy combinations and personalized treatments involving T cells.

But when it comes to the future, Pennell said, identifying targetable genetic alterations in patients and treating them with existing drugs should be a key area of focus.

Studies have shown that probably fewer than half of people with targetable genetic alterations in lung cancer are being identified and never receiving treatment for this, Pennell said, and I think before we move on to the next exciting drug or the next exciting marker, we should spend a little time making sure that every patient is identified and gets access to the treatments that we already have.

Transcription:

We've made such tremendous progress over the last decade. And just it seems like every year, new targets are emerging and new drugs are getting approved. And so, the speed with which we're moving from discovery to actually treating people has been staggering, and I hope that continues.

There continue to be very promising emerging biomarkers including KRAS mutations, again, HER2 mutations. There certainly is lots of room for improving the efficacy of immunotherapy, which can be tremendously life changing and potentially even curative in patients with metastatic disease. But unfortunately, it's only really working in a minority of patients and so lots of room to be improved in that.

I think combinations of immunotherapy and perhaps even more personalized immunotherapy, using T-cells that recognize individual patients tumors, may be the future for this, or personalized tumor vaccines.

But honestly, instead of just focusing on discovering new treatments and new targets, I think we should focus more on applying what we already know. So, we have tremendous treatments for patients with specific subgroups of lung cancer, but studies have shown that probably fewer than half of people with targetable genetic alterations in lung cancer are being identified and never receiving treatment for this. And I think before we move on to the next exciting drug or the next exciting marker, we should spend a little time making sure that every patient is identified and gets access to the treatments that we already have.

Link:
Personalized Medicine, Genetic Testing Could Shape the Future of Non-Small Cell Lung Cancer - Curetoday.com

3D printing or additive manufacturing has opened a new avenue in the personalized patient care. It is still a relatively emerging technology in the global healthcare industry. The market has seen vast potential in technologies that help surgeons and clinicians understand the complexity of the geometry of human organs and offer timely treatment. 3D printing is rising in clinical significance in printing organs that would be transplanted to the diseased populations, should other options be uncertain or exorbitantly costly. 3D-printed implantable organs will no longer be novelty but a necessity, paving way for lucrativeness of the healthcare 3D printing market. Another area where 3D printing is being utilized is printing of drugs and devices by pharmaceutical and medical companies, world over. The increasing trend of precision medicine and personalized treatments has fuelled the evolution of the healthcare 3D printing market.

Read Report Overview - https://www.transparencymarketresearch.com/healthcare-3d-printing-market.html

3D printing technology has helped clinician advance their patient care. New additive manufacturing technologies have acted as key accelerators of patient-specific model. Particularly, healthcare 3D printing will expand the armamentarium for surgeons to substantially expand their knowledge of patient specific anatomy of crucial lungs such as heart and lungs. The growing availability and affordability of 3D printing techniques will help carve out new avenues in the market. Advances in raw materials used, notably in hydrogel, has also catalyzed prospects in the healthcare 3D printing market. Researchers over the past few years have aimed at changing the consistency of 3D printing materials to make them more biologically adaptable as well as functional. This has also helped them to commercialize the printing process. The increasing shift to patient-specific care will increase the use cases of healthcare 3D printing around the world. New 3D printing technologies will pave way to transforming patient-provider relationship in the not-so-distant future. The use of implantable custom devices is a case in point.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=66506

Global Healthcare 3D Printing Market: Overview

The global market for healthcare 3D printing has been rising on account of advancements in the field of medical research, testing, and analysis. 3D printing helps in developing archetypes and blueprints for objects and items, and this technique plays a key role in multiple industries. The use of 3D printing in the field of healthcare has overhauled the growth dynamics of the worldwide healthcare industry. 3D printing helps in development of organ simulations for testing, research, and analysis. Furthermore, the field of medical testing has also gained a strong impetus on account of advancements in the field of healthcare 3D printing. Considering these dynamics, it is safe to ascertain that the global healthcare 3D printing market would grow at a sound pace in the times to follow. The healthcare industry has emerged as the central element in determining the growth dynamics of a regional territory. This is another key driver of demand within the global market for healthcare 3D printing. Improved technologies for 3D printing shall persuade the healthcare fraternity to resort to its usage in the years to come.

Request for Analysis of COVID-19 Impact on Healthcare 3D Printing Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=66506

The global healthcare 3D printing can be segmented on the basis of the following parameters: North America, Latin America, the Middle East and Africa, Europe, and Asia Pacific. The growth of the global healthcare 3D printing can be gauged with the help of the aforementioned segments.

A report added by Transparency Market Research (TMR) on the global healthcare 3D printing market is a holistic description of the forces of demand and supply. The report sheds light on the influence of various external forces on the global healthcare 3D printing market. Moreover, the regional segments within the global healthcare 3D printing market have also been enunciated therein. A list of the leading companies in the global healthcare 3D printing is also a part of the report.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=66506

Global Healthcare 3D Printing Market: Trends and Opportunities

The presence of a stellar healthcare sector that focuses on development of models and archetypes for analysis and research has aided market growth. 3D printing helps in training of medical professionals and doctors with the help of simulated models of body parts. This factor has led to the increased usage of healthcare 3D printing across the world.3D printing also helps in performing knee and hip implants which is another key driver of demand within the global healthcare 3D printing market. There is little contention about the inflow of massive revenues in the global healthcare 3D printing market.

Global Healthcare 3D Printing Market: Market Potential

The global healthcare 3D printing market has generated a plethora of opportunities for improved research and testing within medicine. This factor has had a direct impact on the growth of the global healthcare 3D printing market. Furthermore, the need to develop close archetypes of key body parts such as lungs, heart, and spine has also generated demand within the global healthcare 3D market.

Pre Book Healthcare 3D Printing Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=66506&ltype=S

Global Healthcare 3D Market: Regional Outlook

On the basis of geography, the global healthcare 3D printing market can be segmented into North America, Latin America, the Middle East and Africa, Europe, and Asia Pacific. The market for healthcare 3D printing in North America is projected to grow on account of advancements in the field of medical research and testing.

Global Healthcare 3D Market: Competitive Landscape

Some of the key vendors in the global healthcare 3D printing market are Bio-Rad Laboratories, SOLS, Organovo, Simbionix, RegenHU Ltd.,and Metamason.

Browse More Reports by Transparency Market Research:

Digital Blood Pressure Monitor Market: https://www.transparencymarketresearch.com/digital-blood-pressure-monitor-market.html

Dialysis Catheters Market: https://www.transparencymarketresearch.com/dialysis-catheters-market.html

Necrotizing Fasciitis Treatment Market: https://www.transparencymarketresearch.com/necrotizing-fasciitis-treatment-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Mr. Rohit BhiseyTransparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

Read the original post:
Healthcare 3D Printing Market: Increasing trend of precision medicine and personalized treatments has fuelled the evolution of the market - BioSpace

Personalized and precision medicines are exciting fields that focus on the development of treatment and prevention strategies for a single patient or patient group. The treatments are developed using cutting- edge technologies such as genomic sequencing and genetic engineering, helping to account for the individual variability in both patient and disease characteristics.

This has gained a lot of attention in recent years due to revolutionary breakthroughs in debilitating chronic diseases such as cancer. Traditionally, cancer patients are treated using one size fits all interventions like chemotherapy, radiotherapy and surgery. These vary in their effectiveness and result in damage to healthy tissues.

Personalized and precision medicine, however, can offer specialized treatments that target the patients unique cancer subtype, its genetic mutations, and the affected tissues.

These therapies involve novel pathways and complex processes to aid and deliver treatment, making each therapy a service in its own right. They depend on many touchpoints, stakeholders, partnerships and interdependencies to treat patients.

As a result, designing suitable services to support patients, caregivers and healthcare providers throughout the treatment pathway is essential. However, doing so successfully depends on understanding how to best approach the design of services in this challenging landscape.

Optimizing the service behind the personalized and precision medicine is crucial for turning the treatment into a viable and differentiated option for patients. To make a real difference and ensure the therapy is competitive, we need to adopt a service design approach.

Service design is a multidisciplinary art and science that enables us to take a holistic view of the service experience, along with a deep understanding of the target groups, such as patients and healthcare professionals, and the context they operate in. This can include using empathic methodologies, such as in-depth interviews and field studies.

Gaining a comprehensive understanding of the customers needs, how they experience the current service, and how future services address their unmet needs.

Involving different stakeholders throughout the design process to gain a wide range of knowledge and expertise, and to further drive customer-centricity across the business.

Using visual tools such as sketches, maps and prototypes to improve and ease communication and collaboration between the different stakeholders involved in the creative process (surpassing language and knowledge boundaries).

Following a learning-by-doing approach via continuous prototyping and testing to evaluate solutions before investing time and resources on development.

Understanding how the customer experiences the whole service journey and then identifying insight gaps and opportunities for service innovation by looking at the big picture.

Personalized and precision medicines are naturally patient-centered (compared to traditional pharmaceuticals), as the individual patient is central to the product design. Taking this empathic approach throughout the design process provides a deeper understanding of those needs as well as their context.

This means not only adopting collaborative thinking during the design phase but also during production and development.

To deliver these unique therapies to patients, pharmaceutical companies must partner with a wide range of specialized third parties including laboratories, manufacturers, shipping and storing providers.

Looking at the entire service and all of its touchpoints from above is crucial

By engaging with multidisciplinary teams from all levels across the organization, as well as numerous stakeholders during the co-creation process, you will increase the organizations knowledge and expertise, resulting in better and more fit-for-purpose solutions. Bring this sense of collaboration into the design process to encourage a higher level of consistency, placement and commitment to the patient and ensure they are at the center of the service philosophy.

Novel therapies require designers to be adaptive. New developments such as changes in the supply chain, shorter genomic sequencing process or the need for an additional quality assurance step, often lead to changes to the envisaged treatment pathway. As a result, it is necessary to have a view of the whole service, in one place, which can be continuously updated.

Visual tools such as customer journey maps and service blueprints are a core part of service design. Journey maps (such as the one featured on p.16) provide an overarching view of the customer experience, along with the pain points, gaps, unmet needs and opportunities for engagement. Service blueprints visualize the process behind the service and the people impacted by it. These tools not only make it easier to understand the service, but they can also help simplify communication and increase alignment between the many individuals engaged in the project.

For personalized and precision medicines, patient journeys and service blueprints can help capture the front-end of the service, which is visible to patients, and the back-end processes, which are used by healthcare professionals. This gives us insights into the interactions, touchpoints and relationships between the patient and various stakeholders, such as the different healthcare professionals, carers and patient groups. Looking at the entire service and all of its touchpoints from above is crucial for making improvements that enrich the customer experience.

CAR-T is a new individualized cancer immunotherapy that has taken precision medicine to a new level. In a nutshell, CAR-T therapy involves extracting T-cells (a type of white blood cells that play a key role in immune response) from the patient, genetically engineering them to target the cancer cells and infusing them back into the patients body.

The CAR-T treatment pathway for a blood cancer involves a uniquely large number of stakeholders, touchpoints and interdependent processes that take place both in the front-end (i.e. visible to the patient) and back-end (i.e. visible to healthcare professionals). Below is a high- level overview of a typical CAR-T journey that can illustrate this complexity:

Click here to read the full article

Read more here:
In the precision medicine era, the line between products and services is blurred - - pharmaphorum

DENVER--(BUSINESS WIRE)--Today ClinOne announced a strategic partnership with CQuentia to bring focused and personalized molecular testing to clinical trial patients. ClinOnes mission is to simplify and accelerate clinical trials for those conducting, participating in and benefiting from clinical studies in onsite, remote, and strictly virtual settings. Our goal is to increase patient access to life changing clinical trials, while continually analyzing operations and developing workflows and capabilities to minimize our clients costs, explains Rob Bohacs, ClinOnes CEO. Partnering with a laboratory such as CQuentia, provides a depth of diagnostic testing that expands ClinOnes offering and brings comprehensive lab solutions directly to the patients.

ClinOne continuously evaluates the market for innovative companies and products to add to its suite of e-clinical technologies. CQuentia is a thought leader in genomic testing and a natural fit, given their comprehensive COVID-19 testing capabilities offered at or near patients homes, explains Dr. Elizabeth Esterl, ClinOnes VP of Operations and Research.

CQuentia is a next-generation sequencing FDA CLIA laboratory and data service that brings a sophisticated precision medicine platform to ClinOnes suite of resources. Among the tests conducted by CQuentia and made available through ClinOne are COVID-19 RT-PCR and Antibody tests, Respiratory Pathogen Panel (RPP) and Pharmacogenomic testing (PGx). CQuentias testing improves the overall well-being of patients by reducing risk and enhancing safety protocols. Esterl explains that such actionable and customized clinical information aligns with our clients to expand virtual clinical trials, by enhancing screening, increasing enrollment and keeping participants actively engaged throughout the trial period.

What separates CQuentia from other testing laboratories is our platform agnostic approach to deliver solutions and our ability to create personalize client specific reports and alerts which plays to ClinOnes strengths and uniqueness as they bring mission-critical clinical study details to clients, research sites and patients. We are motivated by the change we can make in peoples lives through this collaboration, explains Alan Meeker, CQuentia CEO.

About ClinOne

ClinOne is a suite of technologies created to improve access to mission-critical clinical study details, manage research site workflow, and provide patients with a solution to manage the clinical trial journey. The companys sole mission is to simplify and accelerate clinical trials through a single, unified central clinical trial operating system between sponsors, research sites and patients. Today, 45 global sponsors and 2,000 research institutions across 55 countries rely on ClinOnes technology. For more information visit http://www.clinone.com.

About CQuentia

CQuentia is a privately-held molecular testing and sequencing laboratory, positioned to provide doctors, governments, hospitals, payers and employers with rapid, reliable results. CQuentia provides precision medicine, data banking and infection identification, thus enabling clients to make informed clinical decisions, improve outcomes and deliver overall value throughout the healthcare continuum. For more information please visit http://www.cquentia.com

See the rest here:
ClinOne Partners with CQuentia to Add COVID-19 and Comprehensive Precision Medicine Testing to Their Suite of Clinical Trial Operating Services and...